AU2018306614B2 - Methods and compositions for heterologous repRNA immunizations - Google Patents

Methods and compositions for heterologous repRNA immunizations Download PDF

Info

Publication number
AU2018306614B2
AU2018306614B2 AU2018306614A AU2018306614A AU2018306614B2 AU 2018306614 B2 AU2018306614 B2 AU 2018306614B2 AU 2018306614 A AU2018306614 A AU 2018306614A AU 2018306614 A AU2018306614 A AU 2018306614A AU 2018306614 B2 AU2018306614 B2 AU 2018306614B2
Authority
AU
Australia
Prior art keywords
composition
reprna
leu
ivt
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018306614A
Other languages
English (en)
Other versions
AU2018306614A1 (en
Inventor
Darrell J. Irvine
Tasuku KITADA
Mariane Bandeira MELO
Ely Blanton PORTER
Marijn Van Der Neut Kolfschoten
Ronald Vogels
Ron Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Massachusetts Institute of Technology
Original Assignee
Janssen Vaccines and Prevention BV
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV, Massachusetts Institute of Technology filed Critical Janssen Vaccines and Prevention BV
Publication of AU2018306614A1 publication Critical patent/AU2018306614A1/en
Application granted granted Critical
Publication of AU2018306614B2 publication Critical patent/AU2018306614B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018306614A 2017-07-28 2018-07-27 Methods and compositions for heterologous repRNA immunizations Active AU2018306614B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US62/538,070 2017-07-28
US201762546259P 2017-08-16 2017-08-16
US62/546,259 2017-08-16
PCT/US2018/044075 WO2019023566A1 (en) 2017-07-28 2018-07-27 METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP

Publications (2)

Publication Number Publication Date
AU2018306614A1 AU2018306614A1 (en) 2020-01-30
AU2018306614B2 true AU2018306614B2 (en) 2024-08-29

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018306614A Active AU2018306614B2 (en) 2017-07-28 2018-07-27 Methods and compositions for heterologous repRNA immunizations

Country Status (12)

Country Link
US (2) US11235051B2 (https=)
EP (1) EP3658179B1 (https=)
JP (1) JP7311489B2 (https=)
KR (1) KR102806640B1 (https=)
CN (1) CN111163799A (https=)
AU (1) AU2018306614B2 (https=)
BR (1) BR112020001052A2 (https=)
CA (1) CA3071011A1 (https=)
IL (1) IL272281B2 (https=)
MA (1) MA49693A (https=)
SG (1) SG11202000019RA (https=)
WO (1) WO2019023566A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021010611A2 (pt) * 2018-12-14 2021-08-24 Glaxosmithkline Biologicals S.A. Composições e métodos de vacina de reforço (prime boost) heterólogo
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020146700A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Lipid nanoparticles
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
AU2021236068A1 (en) * 2020-03-09 2022-10-06 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4196128A4 (en) 2020-08-14 2024-06-12 Arcturus Therapeutics, Inc. METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES
JP2024509769A (ja) 2021-02-23 2024-03-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
US20240301385A1 (en) 2021-03-22 2024-09-12 LifeEDIT Therapeutics, Inc. Dna modifying enzymes and active fragments and variants thereof and methods of use
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
US20240400619A1 (en) * 2021-09-02 2024-12-05 Replicate Bioscience, Inc. Modified alphaviruses with heterologous nonstructural proteins
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
CN119317430A (zh) * 2022-04-26 2025-01-14 斯特兰德生物科技公司 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
WO2003104467A1 (en) 2002-04-25 2003-12-18 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1687033A4 (en) 2003-11-12 2008-06-11 Us Navy IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP2146760B1 (en) 2007-04-30 2018-10-10 Medtronic MiniMed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
CA2768186A1 (en) * 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
MX342608B (es) 2010-07-06 2016-10-06 Novartis Ag * Particulas de suministro similares a viriones para moleculas de arn de autorreplicacion.
DK2655604T3 (en) * 2010-12-14 2018-08-06 Us Gov Health & Human Services ADENOVIRUS SEROTYPE-26- AND SEROTYPE-35-FILOVIRUS VACCINES
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
CA2960096A1 (en) * 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
BE1023877B1 (fr) * 2015-05-21 2017-09-01 Glaxosmithkline Biologicals Sa Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus

Also Published As

Publication number Publication date
EP3658179C0 (en) 2025-09-17
EP3658179A1 (en) 2020-06-03
CN111163799A (zh) 2020-05-15
MA49693A (fr) 2020-06-03
JP7311489B2 (ja) 2023-07-19
US20220111033A1 (en) 2022-04-14
AU2018306614A1 (en) 2020-01-30
US11964007B2 (en) 2024-04-23
SG11202000019RA (en) 2020-02-27
IL272281B2 (en) 2023-04-01
KR20200037818A (ko) 2020-04-09
CA3071011A1 (en) 2019-01-31
JP2020528911A (ja) 2020-10-01
US20200230225A1 (en) 2020-07-23
IL272281A (en) 2020-03-31
US11235051B2 (en) 2022-02-01
IL272281B (en) 2022-12-01
EP3658179B1 (en) 2025-09-17
KR102806640B1 (ko) 2025-05-12
BR112020001052A2 (pt) 2020-09-08
WO2019023566A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
AU2018306614B2 (en) Methods and compositions for heterologous repRNA immunizations
AU2003297039B2 (en) Multi-antigenic alphavirus replicon particles and methods
AU2007296489B2 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EP2066346B1 (en) Alphavirus replicon particles encoding il-12 as immunological adjuvants
JP2023534900A (ja) 自己増幅ｓａｒｓ－ｃｏｖ－２ｒｎａワクチン
EP1069908B1 (en) Cancer vaccine comprising alphavirus replicon particles
US6844188B1 (en) Methods and modified cells for the treatment of cancer
EP4648781A1 (en) Recombinant modified sarna (vrp) for cancer vaccine
HK40031089B (en) Methods and compositions for heterologous reprna immunizations
HK40031089A (en) Methods and compositions for heterologous reprna immunizations
EA043316B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
EP4612305A1 (en) Binary self-amplifying nucleic acid platform and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)